ロード中...
State of the art in CAR T cell therapy for CD19(+) B cell malignancies
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell malignancies, multiple clinical trials of CAR T cell...
保存先:
| 出版年: | J Clin Invest |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Clinical Investigation
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7108913/ https://ncbi.nlm.nih.gov/pubmed/32235098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129208 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|